Despite these doubts, reliance on PD-L1 IHC for predicting response of NSCLC to IMs means it is imperative that, in the absence of alternative proven biomarkers, every effort should be made to maximise its utility in guiding clinical decision-making. This evidence concerns the gene CD274 and non-small cell lung carcinoma.